REQUEST personal input for Patient Group Submission: HOLKIRA PAK

Do you want new hepatitis C treatment, HOLKIRA PAK™ to be covered by BC PharmaCare? BC PharmaCare has issued a call for Patient Input into whether they should cover AbbVie’s new hepatitis C treatment, HOLKIRA PAK™ (ombitasvir, paritaprevir, ritonavir, and dasabuvir [±ribavirin]). HepCBC is going to make a submission to BC PharmaCare, and URGENTLY requests input from those who have, or have ever had hepatitis C (and their caregivers). Our submission is only

REQUEST Patient input for eltrombopag (REVOLADE) for LOW PLATELETS

Low platelets? BC PharmaCare is considering reimbursement to people with hepatitis C for REVOLADE™ (eltrombopag olamine), a drug made by Glaxo Smith Kline (GSK). Until now, unless they have 3rd party (private) insurance, patients have had to pay for this drug out-of-pocket. To create a good Patient Group Submission to support this welcome change, HepCBC needs your individual input BEFORE MIDNIGHT Sunday FEBRUARY 15th, 2015.  TO MAKE A SUBMISSION... Here ar

URGENT REQUEST for patient input into INTERFERON-FREE HCV 3-drug combo by AbbVie

We've been asked by CADTH* to do a Patient Group Review of the new INTERFERON-FREE 3-drug combo ombitasvir (ABT-267), paritaprevir (ABT-450)+ritonavir, and dasubuvir (ABT-333) which was developed for Chronic Hepatitis C by pharmaceutical company, AbbVie. We urgently request input from individual HCV+ people with any genotype (both those who have and have not tried this drug combination). For background info see http://hepcbc.ca/contribute-to-abbvie-3d-su

URGENT REQUEST for patient input into INTERFERON-FREE HCV drug combo: sofosbuvir+ledipasvir

We've been asked by CADTH* to do a Patient Group Review of the new INTERFERON-FREE drug combo sofosbuvir and ledipasvir (also known as SOVALDI and GS-5885) for Chronic Hepatitis C, developed by Gilead Sciences. We urgently request input from individual HCV+ people (both those who have and have not tried this drug combination, any genotype). For background info see http://hepcbc.ca/contribute-sofosbuvir-ledipasvir-submission-cadth/. For the actual que

Review new drugs for LOW PLATELETS and HEPATIC ENCEPHALOPATHY

The Canadian Drug Review (CADTH) has announced two more new drugs for people with hepatitis C. Both need our patient group input BEFORE MIDNIGHT Tuesday AUGUST 26th! Revolade (Promacta in the USA or "eltrombopag olamine") by Glaxo Smith Kline, and Zaxine (Xifaxan in the USA or "rifaximin") by Salix Pharmaceuticals, are not the "cures" we have all been focusing on recently. Instead, Revolade is used in the treatment of people who are experiencing Thrombocyt

CADTH simeprevir (GALEXOS) news!

The Canadian Drug Review's CDEC Board approved simeprevir (GALEXOS) on June 18th, 2014, and has sent HepCBC a thank you letter for its simeprevir submission. Simeprevir (GALEXOS) is a new hepatitis C drug for genotype 1 infection which, at this point at least, is to be used in a triple therapy along with interferon alpha and ribavirin. This drug, developed by Janssen Pharmaceuticals and marketed in the USA as OLYSIO, is also being recommended in the US and

SOVALDI: Request personal input into Patient Group Submission

Link to July 3, 2014 WEBINAR about Sovaldi by Dr. Alnoor Ramji, co-hosted by HepCBC and the Pacific Hepatitis C Network If you want BC PharmaCare to cover sofosbuvir (SOVALDI™) treatment (from Gilead Sciences), read carefully: HepCBC needs to send BC PharmaCare a really good patient group submission. We need your help before July 10th. This is incredibly important, and every voice we can include makes our submission better, plus the greater number of voice

SOVALDI (sofosbuvir) WEBINAR July 3, noon (PST) with Dr. Alnoor Ramji: FREE, public invited

HepCBC is co-hosting a FREE Webinar with the Pacific Hepatitis C Network on July 3rd at noon Pacific time. Dr. Alnoor Ramji will present the most accurate and most current information about SOVALDI (sofosbuvir), and will be available to answer your questions. REGISTRATION INFORMATION: Pre-register/Sign-in (anytime before Webinar):https://cc.readytalk.com/cc/s/registrations/new?cid=nbgs45xryxtl Step 1 (at 11:55 am July 3rd): Dial-in (US & Canada): 866-7

PATIENTS, CAREGIVERS: HepCBC NEEDS YOUR INPUT RE: SIMEPREVIR

Simeprevir (trade name GALEXOS™, produced by Janssen, Inc.) was recently approved for use in Canada to treat hepatitis C, but BC PharmaCare doesn't cover it yet. Like similar drugs telaprevir/INCIVEK™ and boceprevir/VICTRELIS™, simeprevir is generally given to genotype 1 patients for several weeks in combination with two other medications (hence the name, "Triple Therapy"). In Triple Therapy with simeprevir, the drug is taken once a day (one pill) along wi

URGENT REQUEST FOR YOUR INPUT into a new HCV drug, SOFOSBUVIR

On October 1, 2013 the Canadian Agency for Drugs and Technologies in Health (CADTH) released a call for patient input into Gilead Science's new HCV drug, SOFOSBUVIR. In order to prepare our Patient Group submission by CADTH's October 23rd (noon, PST) deadline, HepCBC is ASKING for INPUT from HCV+ people and caregivers from throughout Canada, by Sunday, October 20th (midnight, PST). CLICK HERE to ADD YOUR VOICE to HepCBC's group submission which will help d